Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma

TL;DR: The current concept of developing YKL-40 as one of the most promising serum markers for glioblastoma is reviewed, the recent advances on understanding the role of YKl-40 in gliomagenesis, and the promising evidence emerging from preclinical models on using this protein as a target for anti-glioma therapy are reviewed.

TL;DR: Investigation of whether subclasses of newly diagnosed GBMs could be assessed and assigned by application of standard pathology laboratory procedures found Immunohistochemistry (IHC)-based profiling was found to be analogous to transcription-based profiling using a 9-gene transcriptional signature for PN and MES subclasses, and a novel, minimal IHC-based scheme for subclass assignment for GBMs is proposed.

TL;DR: It is shown that G SCs retained both neurosphere formation and tumor initiation abilities after short or long term serum exposure, and exposure to serum containing media result in aberrant differentiation and activation of alternative oncogenic pathways in GSCs.

TL;DR: The gasdermin (GSDM) family act as executioners during pyroptosis in glioma and its role in its expression and biological role remain to be determined as mentioned in this paper.

TL;DR: Details of the aims and methods of Bioconductor, the collaborative creation of extensible software for computational biology and bioinformatics, and current challenges are described.

TL;DR: DAMID is a web-accessible program that integrates functional genomic annotations with intuitive graphical summaries that assists in the interpretation of genome-scale datasets by facilitating the transition from data collection to biological meaning.

TL;DR: A robust gene expression-based molecular classification of GBM into Proneural, Neural, Classical, and Mesenchymal subtypes is described and multidimensional genomic data is integrated to establish patterns of somatic mutations and DNA copy number.

TL;DR: Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylation of theMGMT promoter did notHave such a benefit and were assigned to only radiotherapy.